What Spazmol Treats: Main Uses and Benefits

Spazmol is generally used to provide symptomatic relief across therapeutic domains where pain is linked to involuntary smooth muscle spasms. The combination contributes to easing the spasm and reducing associated general discomfort. The combination is considered relevant for the pain of distressing abdominal cramps, including menstrual and urinary tract spasm.

Symptom Management and Clinical Contexts

This medicine is applied in clinical settings that involve acute or unstable symptom patterns, such as pronounced, sudden-onset spasms known as colic. It is commonly used across conditions presenting with acute episodes like renal colic and biliary colic. It is also applied across domains where additional symptomatic support is needed for recurrent or episodic abdominal cramping, gut spasms, and the cramp-like symptoms of dysmenorrhea.

The primary therapeutic focus of this medication is to help address symptoms that may appear suddenly and can create noticeable interference with daily stability. It offers symptomatic relief that helps patients cope more steadily with these difficult, acute episodes and supports patients during periods of heightened discomfort.

“The combination is relevant for easing challenging symptomatic phases associated with involuntary muscle contractions.”

---

Quick Summary of Therapeutic Focus

Symptom Domain	Primary Conditions/Scenarios	Benefit Provided
Visceral Cramping	Renal Colic, Biliary Colic, Intestinal Spasms	Provides support that helps ease the overall symptom burden
Pelvic Discomfort	Dysmenorrhea (Menstrual Cramps)	Contributes to improved comfort during periods of heightened symptoms

Regulatory References

1. Philippine FDA Patient Information Leaflet

Population Eligibility and Contraindications

The official regulatory documentation for Spazmol (Hyoscine Butylbromide and Paracetamol combination) defines strict population-based eligibility rules and absolute prohibitions for its use.

Age Group	Eligibility Status
Children under 10 years	Not suitable/Not recommended (lack of established data)
Adolescents and Adults	Allowed under standard labeled conditions
Older Adults	Allowed; generally, no dose adjustment is necessary

Absolute Contraindications

Spazmol is strictly contraindicated and must not be used by patients presenting with the following conditions:

• Known hypersensitivity to either Hyoscine Butylbromide or Paracetamol.
• Underlying conditions sensitive to anticholinergic effects, including myasthenia gravis, untreated narrow-angle glaucoma, and pathological tachyarrhythmia.
• Conditions involving physical obstruction, such as mechanical stenosis in the gastrointestinal tract, paralytic or obstructive ileus, and megacolon.
• Severe organ dysfunction, specifically severe hepatocellular insufficiency.

Restricted or Conditional Use

Use is not recommended or requires explicit medical supervision in other populations. Use during pregnancy is generally not recommended unless the potential benefit is determined to outweigh the risk. Similarly, use during lactation is often advised to be avoided as a precautionary measure. Caution is required in patients with impaired liver or kidney function, as the Paracetamol component necessitates careful monitoring and potential dose adjustment.

Spazmol contains two active components, Hyoscine Butylbromide and Paracetamol, leading to an interaction profile structured by two main regulatory domains: additive effects and metabolic processing.

Additive Pharmacodynamic Effects

Co-administration with other medicines that possess anticholinergic properties may result in the intensification of the effects of Spazmol’s anticholinergic component. Regulatory documents list substances such as tri- and tetracyclic antidepressants, antihistamines, quinidine, and certain antipsychotics as having this potential. Conversely, concomitant use of dopamine antagonists like metoclopramide may diminish gastrointestinal effects.

Metabolic and Exposure Restrictions

The Paracetamol component carries strict warnings regarding metabolic interactions. It is prohibited to co-administer Spazmol with any other product containing Paracetamol to avoid exceeding the maximum daily dose. The hazard of toxicity is documented as increased when co-administered with liver enzyme inducers, including certain anti-epileptics (e.g., phenobarbitone, carbamazepine) and the herbal product St. John's Wort. The risk of overdose is also documented as higher in patients with chronic alcoholism or severe hepatic impairment.

Pharmacokinetic and Timing Constraints

Interaction patterns also exist concerning drug exposure. Metoclopramide and domperidone accelerate the rate of Paracetamol absorption, while cholestyramine reduces it. This reduction is significant enough that regulatory guidance requires that cholestyramine intake be separated by at least one hour from the intake of the Paracetamol component. Other agents, such as probenecid, are documented to reduce the clearance of Paracetamol. Furthermore, prolonged, regular use of the Paracetamol component may enhance the anticoagulant effect of warfarin and other coumarins.

How Spazmol Works: Biological Mechanism

Spazmol acts by targeting the parasympathetic nervous system at a molecular level to modulate smooth muscle activity. Its action is centered on two key mechanistic domains that result in a physiological shift toward decreased smooth muscle tone and reduced involuntary contraction.

---

Blocking Signals for Smooth Muscle Contraction

Spazmol functions as a competitive antagonist for muscarinic acetylcholine receptors ( M1, M2, M3) located on the smooth muscle cells of the gastrointestinal and genitourinary tracts. By occupying these receptors, the drug suppresses the activity of the neurotransmitter acetylcholine (ACh), which is the primary molecular signal for contraction. This molecular blockade directly inhibits the propagation of excitatory nerve impulses to the muscle, which is the initial step in the mechanistic cascade.

---

Modulating Involuntary Muscle Activity

The resulting effect of muscarinic receptor antagonism is a reduction in the intrinsic tone and contractility of the smooth muscle tissue. This mechanism modulates excitatory signaling, which results in a decrease of excessive and uncoordinated smooth muscle contractions (hypermotility). The physiological consequence of this action is the decrease of involuntary muscle contraction, resulting in a net shift toward decreased muscle activity within the targeted pathways.

The administration of Spazmol is governed by specific guidelines regarding route, dosage, frequency, and duration. These instructions differ based on whether the oral combination tablet (Hyoscine Butylbromide + Paracetamol) or the parenteral injection (Hyoscine Butylbromide monotherapy) is used.

Official Administration Routes and Dosing

Formulation	Approved Route	Standard Adult Dose	Max Daily Dose	Duration Rule
Oral Tablet (10 mg / 500 mg)	Oral (swallowed whole)	1 to 2 tablets per dose	6 tablets	Short-term use only; generally not for more than 3 days without a prescription.
Parenteral Injection (20 mg / mL)	Slow Intravenous (IV), Intramuscular (IM)	20 mg to 40 mg per dose	100 mg	Should not be taken on a continuous daily basis or for extended periods without investigation.

---

Frequency, Timing, and Specific Conditions

For the oral tablet, the dose is taken up to three times daily, with guidelines specifying a minimum interval between administrations to ensure the total daily dose limit is not exceeded. The tablets may be taken with or without food and must be swallowed whole with adequate water. They are generally not recommended for children under 10 years of age.

For the parenteral injection, administration must be performed slowly via the intravenous route and is intended for use in a setting where a doctor’s supervision and patient monitoring are available. The dose may be repeated after half an hour if necessary for acute management, up to the maximum daily limit. If a dose of the oral tablet is missed, the patient should skip that dose and continue with the next scheduled dose; doubling the dose is strictly prohibited.

These instructions establish the precise parameters—route, dose, frequency, and duration—under which the medicine is used, differentiating between out-patient self-administration and supervised clinical use.

Research Evidence / Overview of Studies for Spazmol

This section provides an overview of the types of research and clinical studies that have studied Spazmol (the combination of an antispasmodic and an analgesic) to understand the research base for specific conditions, as documented in scientific and regulatory sources. This information describes group patterns observed in research and research does not determine whether an individual will respond similarly.

---

Evidence for Use in Recurrent Crampy Abdominal Pain

Research was studied for recurrent crampy abdominal pain in studies that are typically short-to-intermediate term, often utilizing placebo-controlled Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in adults. Researchers monitored outcomes related to physical discomfort, primarily focusing on measured changes in pain intensity using standardized scales like the VAS.

The studies focused on defined time intervals and reported how symptoms evolved in the observed populations following study drug administration. Findings described patterns observed in the studies related to acute episodes of abdominal cramping. Further real-world patient surveys have also been applied in studies examining patient-reported experiences in observational settings, contributing to the broader evidence landscape for short-term use.

---

Evidence for Use in Primary Dysmenorrhea (Menstrual Cramps)

Spazmol was studied for Primary Dysmenorrhea, a condition characterized by fluctuating or episodic manifestations. Research has included short-term, acute RCTs that explored the management of pain during the menstrual cycle. These studies monitored patient-reported outcomes describing perceived discomfort. Researchers also looked at outcomes reflecting daily functioning or activity level, assessing how the study drug was associated with these measures.

Studies exploring short-term symptom changes reported how symptoms evolved in the observed populations when compared to a placebo or other common pain-relief medicines. The research was relevant in trials assessing short-term or episodic symptom patterns, providing insight into acute changes.

---

Research Gaps and What Remains Uncertain about Spazmol

Scientific literature and regulatory reviews describe several areas where the evidence landscape for Spazmol could be expanded. Certainty remains low for certain aspects of use.

• Long-term effects are not fully established because the follow-up durations were limited in the primary efficacy studies. Existing studies provide limited insight into whether the measured changes are maintained after extended periods of time or repeated use over many months.
• Data are still emerging regarding the exact role of the fixed-dose combination in the context of specific, diagnosed conditions like biliary or renal colic. In these areas, the evidence for the combination product is less direct than the established research on the individual antispasmodic component.
• Data for certain groups remain insufficient, particularly for Children and Young People, and specific studies focusing on older adults with potential comorbidities are often absent or insufficient in the cited evidence.

Common questions about Spazmol (FAQ)

Q: How quickly can I expect to notice the effects of Spazmol?

A: The onset of relief for the oral tablet formulation is described in official product information. Regulatory documents indicate that patients can generally expect to notice effects beginning within 15 minutes of administration.

---

Q: Does Spazmol start working immediately after I take it?

A: The effect of the oral tablet formulation is not immediate upon swallowing. Product information states that the medicine is expected to begin working within 15 minutes of being administered.

---

Q: How long does one dose of Spazmol typically last in the body?

A: Official documents on the medicine's chemical profile state that the elimination half-life of the antispasmodic component is approximately five hours. This measurement is related to how long the body takes to clear the substance. The medicine is generally intended for short-term, acute relief of symptoms.

---

Q: Is Spazmol the same as other spasm-relief medicines?

A: According to official documents, Spazmol is a combination medicine containing two active components: an antispasmodic agent and a general analgesic (pain reliever). This dual-action approach, combining two different pharmacological actions, is the structural difference noted in product documents compared to single-ingredient medicines.

---

Q: Is a slight headache a normal expected side effect of Spazmol?

A: Headache is listed as a potential side effect in some official product information documents. Additionally, regulatory guidance notes that nervousness and headache have been documented as possible withdrawal symptoms if the medicine is stopped after prolonged use at high doses.

---

Q: Are there any common over-the-counter pain relievers that interact with Spazmol?

A: Regulatory documents state that the intake of certain other medicines, such as probenecid, may affect the metabolism of the Paracetamol component and could require a dosage adjustment. Generally, there is no widely documented interaction with common non-prescription non-steroidal anti-inflammatory drugs (NSAIDs).

---

Q: Are there known food or drink restrictions when taking Spazmol?

A: Official documents specifically warn against consuming alcohol while taking Spazmol. Alcohol may increase the chance of experiencing certain side effects, such as drowsiness.

---

Q: What happens if I need surgery or dental work while taking Spazmol?

A: Regulatory safety advice states that patients should inform any other doctors, dentists, and pharmacists who are treating them that they are taking Spazmol. This disclosure helps ensure that all professionals involved are aware of the medicine's potential effects and interactions.

---

Q: Why is Spazmol sometimes given before certain medical procedures?

A: Official documents describe that the antispasmodic component of the medication is sometimes used during specific medical imaging procedures. This includes diagnostic procedures like MRI or virtual colonoscopy, as the muscle relaxation is utilized to facilitate image acquisition.

---

Q: Can Spazmol be taken by people who have high blood pressure?

A: Official documents state that caution and medical monitoring are generally necessary for patients with a history of cardiac problems. This includes patients who have high blood pressure (hypertension) or other issues like heart failure.

---

Q: Does Spazmol work on all types of pain or only pain caused by spasms?

A: Spazmol is a combination product designed to address two aspects of discomfort. The antispasmodic component works specifically to relieve pain caused by spasms or cramps. The analgesic component is described in regulatory documents as contributing to general pain relief.

---

Q: Has Spazmol been studied in people with Irritable Bowel Syndrome (IBS)?

A: Official documents related to the monotherapy product (containing only the antispasmodic agent) include its use for the symptomatic relief of Irritable Bowel Syndrome (IBS).

---

Q: Is it normal to feel slightly drowsy after taking Spazmol?

A: Drowsiness or sleepiness is a documented side effect of Spazmol. Regulatory information advises that if you experience this effect, activities that require high alertness, such as driving, should be approached with caution.

---

Q: Are there any signs that Spazmol might not be working for my symptoms?

A: Regulatory documents describe specific symptoms that warrant immediate medical evaluation, such as when severe, unexplained abdominal pain persists, worsens, or is accompanied by signs like fever, nausea, vomiting, or blood in the stool.

---

Q: Does Spazmol have the potential for dependence or addiction?

A: Official patient information, particularly for the injectable formulation, states that there is no evidence that this medicine is addictive. The medicine is intended for short-term, acute relief of symptoms.

---

Q: Is Spazmol available as a generic medicine?

A: Regulatory documents identify Spazmol as a brand-name medication. However, the combination of its two active components is widely recognized and used as a common pharmaceutical standard globally.

---

Q: Why do people sometimes use Spazmol for symptoms other than the main listed use?

A: Regulatory documents clearly define the primary approved purpose of Spazmol as relieving painful spasms in the gastrointestinal and urinary tracts. Its labeled uses include acute spasmodic pain associated with conditions like intestinal cramps and menstrual cramps (dysmenorrhea).

---

Q: Can I take Spazmol if I have a history of heart problems?

A: Official documents state that caution and medical monitoring are generally necessary for patients with a history of cardiac problems. This includes conditions such as heart failure, coronary heart disease, or irregular heart rhythm (cardiac arrhythmia).

---

Q: Does taking Spazmol for a long time reduce its effectiveness?

A: Regulatory guidance indicates that the medicine is not intended for continuous daily use over extended periods. If prolonged use is being considered, ongoing medical investigation and monitoring of blood counts and organ functions (such as liver and kidney) is recommended.

---

Q: Does Spazmol cause constipation or change bowel habits?

A: Yes, constipation is listed as a documented side effect of Spazmol. The medicine works by relaxing smooth muscles, and this can slow down the normal movement of the gut. Official documents advise that caution is generally necessary in patients who have pre-existing conditions such as chronic constipation.

---

Q: Does Spazmol make you feel jittery or nervous?

A: Nervousness is listed in regulatory documents as a possible symptom that may occur when the medicine is abruptly discontinued. This has been documented to occur following prolonged use at high doses.

---

Q: What should I do if I think I'm having a rare or serious side effect from Spazmol?

A: Regulatory documents describe the need for immediate medical evaluation if a severe or serious adverse reaction is suspected, or if new symptoms are noticed. This evaluation is necessary for symptoms like severe skin reactions, signs of liver damage (jaundice), or severe allergic reactions.

---

Q: Is Spazmol approved for use in all countries?

A: Spazmol is a brand-name medication, and its specific formulation and name can vary internationally. Official documents confirm that its regulatory approval status may be different across various countries and regions.

---

Q: Are there any specific lifestyle changes recommended when taking Spazmol?

A: Regulatory patient information includes general advice for managing related symptoms, such as the value of maintaining adequate hydration and, if applicable, addressing constipation.

---

Q: Can Spazmol cause loss of taste or dry nose?

A: Dry nose is listed as a documented anticholinergic side effect of this medication. Dry mouth is also a common side effect, but loss of taste (dysgeusia) is not generally listed in the regulatory documents.

---

Q: Do studies suggest Spazmol is less effective for certain patient populations?

A: Studies documented in the research base note a lack of sufficient data for certain patient groups, particularly children and older adults. The documented research gap indicates that the long-term data related to the drug's use and observed effects in these specific populations is not well-established in the existing evidence.

---

Q: What percentage of users experience the most common side effects of Spazmol?

A: Regulatory agencies classify side effects using standardized terms to describe how often they occur, such as 'Common' or 'Uncommon'. For example, 'Common' generally means the effect is observed in between 1 in 100 and 1 in 10 patients. Specific numerical percentage data for every effect is not consistently provided across all official product information.

Storage and Disposal Requirements

This medicine must be stored strictly according to the official regulatory instructions to maintain stability and effectiveness.

Storage Conditions

Requirement	Official Instruction
Temperature	Store below 25 C or 30 C, depending on the formulation.
Protection	Keep the product in its original package and away from excessive heat or direct sunlight.
Child Safety	Store the medicine out of the sight and reach of children.

Stability and Disposal

The product must not be used after the expiry date shown on the packaging. For the injection formulation, any partially used ampoules must be immediately discarded after use. For disposal of unused or expired product, individuals must ask a pharmacist for guidance. The medicine must not be thrown away via wastewater or with household waste to protect the environment.